Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Danaher Corporation has demonstrated a positive financial outlook, highlighted by an increase in performance obligations, which rose to $4.9 billion in 2Q25 from $4.5 billion in 1Q25. The company's life sciences sector is anticipated to achieve a growth ramp of approximately 4.5% in 4Q25, driven by favorable comparisons in genomics, improved performance in China, and new product launches. Additionally, the Cepheid respiratory segment is expected to perform robustly in the upcoming quarters, projecting revenues of $300-350 million in 3Q25 and $450-500 million in 4Q25, indicating a solid demand trajectory.

Bears say

The financial outlook for Danaher appears negative due to a decline in the percentage of 2Q25 obligations expected to be recognized as revenue within the next 12 months, dropping from 48% to 46%. Additionally, there are significant risks associated with geopolitical disruptions, foreign exchange volatility, and the failure of high-growth end-markets, particularly in China, to recover. Furthermore, the company's recent revenue guidance for the Biotechnology and Life Sciences sector fell below expectations for 3Q25, suggesting underlying challenges that may impact future performance.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $249.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $249.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.